Citi said the rejection prevents Dr. Reddy’s Laboratories from participating in the initial wave of semaglutide in Brazil. Dr. Reddy’s has missed the early opportunity in a competitive market with 16 pending applications in Brazil, Citi’s note said.
Citi said the rejection prevents Dr. Reddy’s Laboratories from participating in the initial wave of semaglutide in Brazil. Dr. Reddy’s has missed the early opportunity in a competitive market with 16 pending applications in Brazil, Citi’s note said.